Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
Newsletters
Training
White Papers
Advertising
Contact Us
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Roche, Biogen Halt Rheumatoid Arthritis Trials After Deaths

Drug Industry Daily

March 9, 2010 | Vol. 9 No. 46

Roche, Biogen Halt Rheumatoid Arthritis Trials After Deaths

Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis (RA) following deaths in Phase III clinical trials.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

BMS, Pfizer Release Strong Efficacy Results for Apixaban to Prevent Stroke Bionovo Drug Gets FDA OK for Phase III Novartis’ Potential Plavix, Effient Competitor Heads to Phase III FDA Reviewing Heart Risk Data for Parkinson’s Drug Stalevo

Home
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.